Evidence map›Paper›PMID 31701353›Full record

ArticleInflammation2020

Salidroside Restores an Anti-inflammatory Endothelial Phenotype by Selectively Inhibiting Endothelial Complement After Oxidative Stress.

Y Wang, Y Su, W Lai, X Huang, K Chu, J Brown, G Hong

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. The EPMA journal · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Y WangCentre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China.
Y SuPeople's Hospital, Fujian University of Traditional Chinese Medicine, No. 602 BayiqiZhong Road, Taijiang, Fuzhou, China.
W LaiCentre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China.
X HuangCentre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China.
K ChuCentre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China.
J BrownCentre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China.
G HongCentre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, No. 1 Huatou Road, Minhou Shangjie, Fuzhou, China. guizhuhong@fjtcm.edu.cn.ORCID http://orcid.org/0000-0003-3932-4777
Fujian University of Traditional Chinese Medicine · CN

Funding

National Natural Science Foundation of China 81473382Young Scientists Fund 81603323
6 · The paper itself

Abstract

Salidroside, an active component of Rhodiola rosea, reduces inflammation and neuronal damage after middle cerebral artery occlusion (MCAO) with reperfusion, partly by inhibiting cerebral complement C3 activation. However, the mechanisms of this inhibition are not fully understood. In this study, we investigated which cerebral cells might contribute to the inhibition of complement by salidroside and the consequences of this inhibition. We used human umbilical endothelial cells (HUVEC) as a model of cerebral endothelium and found that salidroside prevented the increases of C3 and its active fragment C3a, and the associated increases in C1q and C2, otherwise caused by oxygen-glucose deprivation followed by restoration (OGD/R). However, salidroside did not affect C1q, C2 or C3 in astrocytes and microglial BV2 cells after OGD/R. Salidroside also prevented the decreases in CD46 and CD59, and the increases in VCAM-1, ICAM-1, P-selectin and E-selectin caused by OGD/R in HUVEC, which were associated with decreasing LDH release and increasing Bcl-2/Bax ratio. None of these effects of salidroside occurred in the absence of oxygen-glucose restoration. Moreover, salidroside and C3a receptor antagonist reduced the markers of endothelial activation and neutrophil adhesion to HUVEC after OGD/R to similar extents, and their effects were not additive. Correspondingly, salidroside reduced the markers of endothelial activation and neutrophilic infiltration in the rat brains after MCAO with reperfusion. These results suggest endothelium is an important locus of inhibition of complement by salidroside, restoring an anti-inflammatory endothelial phenotype after oxidative stress, partly by inhibiting classical complement activation and partly by increasing CD46 and CD59, in association with anti-apoptotic effects. These endothelial effects may contribute to the protection afforded by salidroside in cerebral ischemia-reperfusion injury.

Indexed as

AnimalsAnti-Inflammatory AgentsApoptosis Regulatory ProteinsBrainCell LineCoculture TechniquesComplement ActivationComplement C3Complement Inactivating AgentsDisease Models, AnimalEndothelial CellsGlucosidesHumansHuman Umbilical Vein Endothelial CellsInfarction, Middle Cerebral ArteryInflammation MediatorsAnti-Inflammatory AgentsApoptosis Regulatory ProteinsC3 protein, humanComplement C3Complement Inactivating AgentsGlucosidesInflammation MediatorsPhenolsrhodiolosidecomplementendothelial cellsinflammationsalidrosidestroke

Identifiers

PMID31701353
OpenAlexW2984798861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.